Greenhouse Gas Verification Statement
Teva Pharmaceutical Industries Ltd

The inventory of Greenhouse Gas emissions in the period
01/01/2021 – 31/12/2021 for
Teva Pharmaceutical Industries Ltd

has been verified in accordance with ISO 14064-3:2019
as meeting the requirements of

GHG PROTOCOL

To represent a total amount of:
574,673 tCO₂e

For the following activities
Pharmaceutical Industries, offices, R&D, centers and logistics centers

Lead Assessor: Soraya del Río Alcalde
Assessor: Andrea Rodicio Lagunilla
Assessor: Germán Soto Fuentes
Technical Reviewer: Paula Gómez Geras

Approved by:
Lourdes Martin Mangas.

Verification Statement Date 21th April 2022

This Statement is not valid without the full verification scope, objectives, criteria and conclusion available on pages 2 to 4 of this Statement.
Schedule Accompanying Greenhouse Gas Verification Statement
Number 02/958/312279-02

Brief Description of Verification Process
SGS has been contracted by Teva Pharmaceutical Industries Ltd. for the verification of direct and indirect carbon dioxide (CO₂) equivalent emissions as provided by Teva Pharmaceutical Industries Ltd. in their GHG Assertion in the form of Greenhouse Gas Emissions Report “GHG Emissions Report 2021” covering CO₂ equivalent emissions.

GHG emissions verified in the period 2021 in the amount of:
574,673 t CO₂ eq,
288,405 t CO₂ eq for Scope 1
286,268 t CO₂ eq for Scope 2

Roles and responsibilities
The management of Teva Pharmaceutical Industries Ltd. is responsible for the organization’s GHG information system, the development and maintenance of records and reporting procedures in accordance with that system, including the calculation and determination of GHG emissions information and the reported GHG emissions.

It is SGS’ responsibility to express an independent GHG verification opinion on the emissions as provided in the Teva Pharmaceutical Industries Ltd. GHG Assertion for the period 01/01/2021 – 31/12/2021.

SGS conducted a third part verification following the requirements of ISO 14064-03:2019 of the provided CO₂ equivalent assertion “GHG Emissions Report 2021” in the period March to April 2022.

The assessment included a desk review. The verification was based on the verification scope, objectives and criteria as agreed between Teva Pharmaceutical Industries Ltd. and SGS on contract date March 28th, 2022.

Level of Assurance
The level of assurance agreed is limited

Scope
Teva Pharmaceutical Industries Ltd. has commissioned an independent verification by SGS of reported CO₂ equivalent emissions arising from their activities, to establish conformance with the requirements of GHG PROTOCOL within the scope of the verification as outlined below. Data and information supporting the CO₂ equivalent assertion were historical in nature and proven by evidence.
This engagement covers verification of emissions from anthropogenic sources of greenhouse gases included within the organization’s boundary and meets the requirements of GHG PROTOCOL.

- The organizational boundary was established following the operational control approach.  
  Title or description of activities: Pharmaceutical Industries, offices, R&D, centers and logistics centers.
- Location/boundary of the activities: International sites including sales offices.
- Physical infrastructure, activities, technologies and processes of the organization.
- GHG sources, sinks and/or reservoirs included (list by scope):
  Scope 1 - stationary combustion, mobile combustion (transport), process emissions, fugitive emissions and refrigerants.
  Scope 2 – purchased electricity, including Non-RA sites Electricity, heat and steam production.
- Types of GHGs included: CO₂, N₂O, CH₄, HFCs, PFCs, SF₆.
- Directed actions: none.
- GHG information for the following period was verified: 01/01/2021 – 31/12/2021.
- Intended user of the verification statement: general public.

**Objective**

The purposes of this verification exercise are, by review of objective evidence, to independently review:

- Whether the CO₂ equivalent emissions are as declared by the organization’s CO₂ equivalent assertion
- That the data reported are accurate, complete, consistent, transparent and free of material error or omission.

**Criteria**

Criteria against which the verification assessment is undertaken are the requirements of GHG PROTOCOL.

**Materiality**

The materiality required of the verification was considered by SGS to be below 10%, based on the needs of the intended user of the GHG Assertion.
Conclusion

Teva Pharmaceutical Industries Ltd. provided the GHG assertion based on the requirements of GHG PROTOCOL.

The GHG information for the 01/01/2021 – 31/12/2021 disclosing gross emissions of 574,673 metric tonnes of CO₂ equivalent are verified by SGS to a limited level of assurance, consistent with the agreed verification scope, objectives and criteria.

SGS’ approach is risk-based, drawing on an understanding of the risks associated with modeling GHG emission information and the controls in place to mitigate these risks. Our examination included assessment, on a sample basis, of evidence relevant to the voluntary reporting of emission information.

**SGS concludes with limited assurance** that the presented CO₂ equivalent assertion based on the process and procedures conducted, **there is no evidence that**

- Is not materially correct and is not a fair representation of GHG data and information
- Has not been prepared in accordance with the related International Standard on GHG quantification, monitoring and reporting, or to relevant national standard or practices.

We planned and performed our work to obtain the information, explanations and evidence that we considered necessary to provide a limited level of assurance that the CO₂ equivalent emissions for the period 01/01/2021 – 31/12/2021 are fairly stated.

This statement shall be interpreted with the CO₂ equivalent assertion of Teva Pharmaceutical Industries Ltd. as a whole.

Note: This Statement is issued, on behalf of Client, by SGS United Kingdom Ltd, Rossmore Business Park, Inward Way, Ellesmere Port, Cheshire, CH65 3EN (“SGS”) under its General Conditions for GHG Validation and Verification Services. The findings recorded hereon are based upon an audit performed by SGS. A full copy of this statement and the supporting GHG Assertion may be consulted at [www.tevapharm.com](http://www.tevapharm.com). This Statement does not relieve Client from compliance with any by laws, federal, national or regional acts and regulations or with any guidelines issued pursuant to such regulations. Stipulations to the contrary are not binding on SGS and SGS shall have no responsibility vis-à-vis parties other than its Client.